The Cullinan
Oncology
Leadership
Team
Diverse Teams Fuel Innovation
With backgrounds as varied as our pipeline, the Cullinan Oncology leadership team’s collective yet distinct experiences are focused on leading through drug discovery, development, and delivery.
Nadim Ahmed
Chief Executive Officer
Leadership
Chief Human
Resources Officer
Chief Scientific Officer
Patrick is the Chief Scientific Officer and a founder of Cullinan Oncology, as well as an Entrepreneur at MPM and BioImpact Capital. An immune oncology pioneer with extensive experience, Patrick has co-founded seven MPM oncology portfolio companies including Harpoon, TCR², iOmx, Maverick, Cullinan Oncology, Aktis Oncology and Werewolf.
Prior to founding Cullinan Oncology and becoming the Chief Scientific Officer, Patrick served as Vice President of Research and General Manager of Amgen Research Munich GmbH and as CSO for Micromet. He earlier headed small-molecule drug discovery at Tularik, a publicly traded biotechnology company acquired by Amgen. Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick holds a Ph.D. in Biology from the University of Munich (LMU) and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty of LMU in Munich, Germany and is an elected member of the German National Academy of Sciences Leopoldina.
Chief Technical
Operations Officer
Kevin holds an M.S. in Chemistry from Northeastern University, Boston and a B.S. in Chemistry from Lafayette College, Easton, PA.
Chief Medical Officer
Dr. Jeffrey Jones has over 15 years of clinical development experience in academia and industry, with skills ranging from clinical trials, drug development, medical education, and healthcare management. Previously, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at Bristol-Myers Squibb, where he led the development and lifecycle management strategy for Reblozyl®. Earlier, Dr. Jones was Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development at Celgene, where he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development.
Before joining the industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, an M.P.H. from the University of Texas School of Public Health and an M.D. from the University of Michigan Medical School, completing his residency in internal medicine at McGill University.
Chief Development Officer
Jennifer is a skilled scientific leader with 17+ years of experience in oncology, immunology, and immune-oncology. Prior to joining Cullinan Oncology, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch and serving on its leadership team, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development.
Previously, during her 10-year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the oncology and immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.
Jennifer received her B.A. in Biology from Princeton University and Ph.D. from the Department of Cell Biology at Albert Einstein College of Medicine and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.
Chief Business Officer
Corinne is highly accomplished in pharmaceutical research and development, oncology and international business development. Prior to joining Cullinan Oncology, Corinne served as Global Head, Business Development and Licensing for Novartis Pharma. In this role, Corinne oversaw the execution and management of over 20 major transactions across multiple therapeutic areas including in-licensing, option and equity deals, spin-outs, and divestments. Corinne started her career as a researcher at AstraZeneca and Imutran, a UK-based biotech company, where she was Research Director. Novartis acquired Imutran in 1996 and Corinne was promoted to CEO of Imutran. Since 2001, Corinne continued to hold increasingly senior leadership positions within Novartis. She was the European Head of the Transplant and Immunology Business, the Global Head Search and Evaluation for Business Development and prior to her last role the Global Head of Pricing and Market Access where she was responsible for the price and access strategies for the entire Novartis portfolio.
Corinne received a B.S. in Biochemistry from the University of Manchester (UK) and conducted her postgraduate research at University College and Middlesex School of Medicine (Ph.D.) and the Charing Cross Sunley Research Centre in London.
Chief Compliance Officer,
and Corporate Secretary
Jackie began her legal career at Kaye Scholer, LLP, and clerked for the Honorable Gladys Kessler of the United States District Court in Washington, D.C. She holds a J.D. and a L.L.M. in international and comparative law from Duke University School of Law and a B.A. from Bucknell University.
Chief Financial Officer
Senior Vice President, Communications
Rose is an expert communications professional in the pharmaceutical and biotech industries. Prior to joining Cullinan Oncology, she held roles of increasing responsibility in Corporate Affairs at Bristol Myers Squibb, with leadership positions in Science and Commercial Communications, Global Hematology, and Corporate Communications. Rose joined Bristol Myers Squibb after leading communications for the U.S. site for Otsuka. Previously, Rose held business communications roles at Sanofi. Rose earned her Master’s degree in Finance from La Salle University in Philadelphia.
Board of Directors
President and Chief Executive Officer
Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology. As President, Hematology at BMS, Nadim oversaw multiple product launches and served as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. Nadim has expertise in various treatment modalities, including small molecules, biologics, and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.
Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping families impacted by homelessness.
After earning a degree in psychology in Hamburg, Thomas began his career with Reemtsma in 1987, where he served as the product manager responsible for the “West” brand, among other duties. In 1991, he moved to Pepsi-Cola Germany, where he served as a marketing manager. In 1993, he was appointed Marketing Director for the entire beverage portfolio. Starting in 1994, he was National Sales and Franchise Director for the retail and restaurant sales of Pepsi-Cola. In 1996, he was appointed General Manager of Pepsi-Cola Germany.
In 1997, Thomas moved to Novartis, where he served as General Manager of Novartis Nutrition for Germany and Austria. In 1998, he assumed worldwide leadership of the Novartis Nutrition Division. In this position, he headed the three business units Medical Nutrition, Health Nutrition, and Consumer Retail Brands, where, among other duties, he was responsible for the leading U.S. baby food brand Gerber. In 1998, he was appointed to the Novartis Executive Committee and from 2000 to October 2007, he served as CEO of the global Novartis pharmaceuticals business. Under his leadership, the company’s revenues more than doubled from U.S. $11 billion to US $22.6 billion, after which he was CEO of the Novartis Consumer Health Division from 2007 to 2009.
From 2009 to 2018, Thomas served as CEO of ProSiebenSat.1 Media SE, and has been a member of the supervisory board of Bayer AG since 2012 as well as a member of Board of Directors at Sivantos (Hearing Aids) since 2016 and GFK since 2017.
David holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. After completing his degree, David began his career at Columbia-Presbyterian Medical Center as an intern in Internal Medicine and became chief resident in the Internal Medicine department during his postdoctoral training. David joined Massachusetts General Hospital in 1998, where he has held positions of increasing responsibility over the past two decades, specializing in the research and treatment of patients with cancer.
Along with his professional experience, David has held many academic posts, including his current position of Shelby Memorial Professor of Medicine in the field of cancer therapeutics at Harvard Medical School. The principal focus of David’s research is the design and implementation of clinical trials in gastrointestinal malignancies.
In addition to his professional, academic, and leadership roles, David devotes much of his time to numerous medical and hospital associations and committees. David is a member of the American Society for Clinical Oncology.
Anne-Marie has more than 20 years of medical experience in experimental medicine and research. She is an internationally trained scientist, thought leader, and senior pharmaceutical executive. She has a successful track record in drug development, companion diagnostic development, and translational medicine across numerous therapeutic areas. Her experience in global regulatory science, medical affairs, business development, alliance management, and global commercial insights conveys her passion for people development, organizational culture, inclusion, and diversity.
Previously, Anne-Marie was Senior Vice President, Global Head of Precision Medicine at Novartis and Vice President, Head of Biomarker Research and Diagnostics at Adaptimmune. In addition to these roles, Anne-Marie’s career also includes a number of university appointments inclusive of teaching and research positions.
She received her undergraduate degree in biomedical sciences from Sheffield Hallam University, Sheffield, UK and a Ph.D. in Immunogenetics from MCP-Hahnemann University in Philadelphia.
Previously, Tony was Global Head, M&A, and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role, he oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care, and generics.
Tony brings more than 30 years of biotech operations and strategic management experience to Cullinan Oncology. He joined Novartis' predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development, and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma) and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group.
Tony has a B.S. in Biological Sciences from the University of Leicester and an M.S. in Physiology from the University of London.
Tony currently serves as Chairman of the Board of Oculis SA and is on the Board of Directors of argenx BV. Tony also serves as an advisor to PJT Ltd, UK.
He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Stephen currently serves on the Board of Directors of NextCure, Inc., Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) and TCR2.
Stephen received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. We believe Stephen is qualified to serve as a member of our Board of Directors due to his extensive experience in the biopharmaceutical industry, including his prior experience as a chief financial officer and other management positions.